TUDOR INVESTMENT CORP ET AL - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
TUDOR INVESTMENT CORP ET AL ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q1 2023$12,187
+86.9%
164,262
+108.8%
0.19%
+46.5%
Q4 2022$6,522
-99.9%
78,688
+302.8%
0.13%
+7.5%
Q3 2022$5,548,000
+95.6%
19,535
+138.7%
0.12%
+62.2%
Q2 2022$2,837,000
+995.4%
8,183
+1536.6%
0.07%
+1750.0%
Q4 2021$259,000
-55.3%
500
-58.3%
0.00%
-55.6%
Q3 2021$580,000
-84.1%
1,200
-85.2%
0.01%
-87.0%
Q2 2021$3,654,000
+1102.0%
8,117
+919.7%
0.07%
+1050.0%
Q1 2021$304,000
-74.7%
796
-79.0%
0.01%
-82.4%
Q4 2020$1,202,000
-19.8%
3,785
-37.4%
0.03%
-47.7%
Q3 2020$1,498,000
+51.2%
6,046
+15.6%
0.06%
-27.0%
Q1 2020$991,000
+144.1%
5,228
+182.7%
0.09%
+394.4%
Q4 2019$406,000
-69.6%
1,849
-71.1%
0.02%
-52.6%
Q2 2019$1,335,000
+53.8%
6,403
-16.8%
0.04%
+111.1%
Q2 2016$868,000
+162.2%
7,700
+120.0%
0.02%
+125.0%
Q1 2016$331,000
-19.5%
3,500
-14.6%
0.01%
-38.5%
Q1 2015$411,000
-20.5%
4,100
-26.8%
0.01%
-27.8%
Q4 2014$517,000
-23.3%
5,600
-22.2%
0.02%
-25.0%
Q3 2014$674,0007,2000.02%
Other shareholders
BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 275,000$18,719,25020.14%
Montanaro Asset Management Ltd 408,800$27,827,0164.90%
Sandhill Capital Partners LLC 613,061$41,731,0913.90%
Pembroke Management, LTD 365,611$24,887,1413.40%
DF DENT & CO INC 3,349,047$227,969,6483.34%
Brown Capital Management 3,158,004$214,965,3323.30%
Ownership Capital B.V. 1,786,273$121,591,6033.05%
STONE RUN CAPITAL, LLC 86,335$5,876,8232.88%
Jackson Square Partners, LLC 1,260,547$85,805,4342.87%
Summit Creek Advisors LLC 284,681$19,378,2362.64%
View complete list of BIO-TECHNE CORP shareholders